Dechra Pharmaceuticals (OTCMKTS:DCHPF – Get Rating) was upgraded by equities researchers at Panmure Gordon from a “hold” rating to a “buy” rating in a research note issued on Thursday, The Fly reports.
Several other analysts have also recently commented on the stock. Liberum Capital upgraded shares of Dechra Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday. Jefferies Financial Group upgraded shares of Dechra Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, October 18th. Berenberg Bank began coverage on shares of Dechra Pharmaceuticals in a research report on Wednesday, October 5th. They set a “hold” rating for the company. JPMorgan Chase & Co. dropped their target price on shares of Dechra Pharmaceuticals from GBX 5,700 ($69.44) to GBX 4,600 ($56.04) in a research report on Tuesday, January 3rd. Finally, Royal Bank of Canada dropped their target price on shares of Dechra Pharmaceuticals from GBX 4,200 ($51.17) to GBX 4,000 ($48.73) in a research report on Thursday, September 15th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $4,300.00.
Dechra Pharmaceuticals Price Performance
OTCMKTS:DCHPF opened at $32.40 on Thursday. The stock’s fifty day moving average price is $32.91 and its two-hundred day moving average price is $36.70. Dechra Pharmaceuticals has a 52-week low of $27.90 and a 52-week high of $57.25.
About Dechra Pharmaceuticals
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies.
- Get a free copy of the StockNews.com research report on Dechra Pharmaceuticals (DCHPF)
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here’s Why
- Carvana Stock Rally, Here’s What You Need to Know
Receive News & Ratings for Dechra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.